Cardiovascular
OUR STRATEGIC OBJECTIVE
Backed by over 40 years’ experience, AstraZeneca is a world leader in cardiovascular (CV) medicines. We aim to build on our strong position, focusing on the growth areas of atherosclerosis (hardening of the arteries), thrombosis (blood clotting), diabetes and atrial fibrillation.
- Crestor sales up 26% to $3.6 billion and Crestor is now approved in every EU country.
- Crestor study demonstrates significant reduction in major cardiovascular events (44% compared to placebo in men and women with elevated hsCRP but low/normal cholesterol levels).
- Atacand sales up 10% to $1.5 billion.
- Worldwide collaboration with Bristol-Myers Squibb to develop and commercialise dapagliflozin expanded to include Japan.
- US submission for fixed dose combination of Crestor and Abbott’s Trilipix™, for the treatment of mixed dyslypidaemia, anticipated for third quarter 2009.
- Toprol-XL US sales down 70% for the full year.
Crestor1 (rosuvastatin calcium) is a statin for the treatment of dyslipidaemia and hypercholesterolemia, and to slow the progression of atherosclerosis.
Atacand2 (candesartan cilexetil) is an angiotensin II antagonist for the first-line treatment of hypertension and symptomatic heart failure.
Seloken/Toprol-XL (metoprolol succinate) is a once daily tablet for 24-hour control of hypertension and for use in heart failure and angina.
Tenormin (atenolol) is a cardioselective beta-blocker for hypertension, angina pectoris and other cardiovascular disorders.
Zestril3 (lisinopril dihydrate), an ACE inhibitor, is used for the treatment of a wide range of cardiovascular diseases, including hypertension.
Plendil (felodipine) is a calcium antagonist for the treatment of hypertension and angina.
1 Licensed from Shionogi & Co. Ltd.
2 Licensed from Takeda Chemicals Industries Ltd.
3 Licensed from Merck & Co., Inc.
THERAPY AREA WORLD MARKET (MAT/Q3/08)
CV is the single largest therapy area in the global healthcare market. World market value of $155 billion. CV disease remains the greatest risk to life for most adults, accounting for 17 million deaths worldwide each year. In the US, 21 million people suffer from diabetes and two in five people with diabetes still have poor cholesterol control, one in three have poor blood pressure and one in five have poor glucose control.
QUICK LINKS
DOWNLOAD REPORT
Our report is available to download in CORPORATE RESPONSIBILITY
Find out more about our commitment to responsible business
GLOSSARY
Abbreviations/expressions and their meanings, when used on this website
FEEDBACK
Your opinions and comments are very important to us
